Lund, Sweden – February 10, 2026 –Active Biotech (NASDAQ Stockholm: ACTI) today received positive feedback on its clinical proof-of-concept trial with tasquinimod in myelofibrosis. The study will now resume recruitment. “We are very happy with the response to our protocol amendments, and we expect to report interim results from the…
The number of shares and votes in Active Biotech AB (publ) has changed as a result of the recently completed rights issue. Today, the last trading day of the month, there are in total 2,636,067,170 shares and votes in Active Biotech. For further information, please contact: Helén Tuvesson, CEO, +46 46…
In accordance with a decision made by the Annual General Meeting held on May 28, 2025, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2025, and the Chairman of the Board. If a shareholder does not exercise its right…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS…
Lund, November 25, 2025, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent and Trademark Office (USPTO) has issued a notification that the company’s patent application related to a pharmaceutical formulation containing tasquinimod will be granted on 2 December 2025 under the patent number 12,485,095. The patent will…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS…
Lund, November 24, 2025 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data with tasquinimod, a small molecule immunomodulator, in myelofibrosis has been published in the American Society of Hematology’s scientific journal Blood Advances. The article, titled Preclinical efficacy of tasquinimod -based combinations in advanced myeloproliferative neoplasms in…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS…
The Extraordinary General Meeting of Active Biotech was held on November 19, 2025. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was resolved to amend the Articles of Association, whereby the limits for the company’s share capital are changed to not less than…
THIRD QUARTER IN BRIEF Active Biotech provided status update for the development of laquinimod in inflammatory eye disorders and tasquinimod in hematological malignancies (July 8) Active Biotech presented positive results from the clinical phase I LION study at AAO 2025 in October (September 10) EVENTS AFTER THE END OF THE…
Lund, November 3, 2025 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that an abstract with preclinical data of tasquinimod in combination with T cell activation has been accepted for presentation at the 67th American Society of Hematology Annual Meeting in Orlando, December 6-9, 2025 (ASH 2025). The abstract demonstrating…
The shareholders of Active Biotech AB (publ), Reg. No. 556223-9227, with its registered office in Lund, Sweden, are invited to the Extraordinary General Meeting of shareholders to be held on Wednesday, November 19, 2025 at 11 a.m. CET in the premises of the Company at Scheelevägen 22, SE-223 63 Lund,…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS…
Lund, September 10, 2025 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced a presentation will be featured highlighting the positive results from the ocular biodistribution LION study at the prestigious American Academy of Ophthalmology 129th Annual Meeting (AAO 2025) in Orlando, Florida, October 18-20. The poster presentation, titled Safety, Tolerability…
SECOND QUARTER IN BRIEF Active Biotech reported positive top-line results from the LION study on ocular absorption and distribution of laquinimod in the eye (May 5) Active Biotech announced that a patent for tasquinimod in myelofibrosis was granted in Europe (May 21) Active Biotech reported study results with tasquinimod in…
Lund, Sweden – July 8, 2025 –Active Biotech (NASDAQ Stockholm: ACTI) today provided a status update of its development programs with laquinimod in inflammatory eye disorders and tasquinimod with the core focus in myelofibrosis. We have communicated progress in the clinical development programs for both drug candidates recently, and a…
Lund, Sweden, June 30, 2025 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that an interview with the investigators of the clinical ocular biodistribution LION study at the International Ocular Inflammation Society (IOIS) meeting, on June 25-28 in Rio de Janeiro, Brazil, is available on the company’s website. The interview…
Lund, June 9, 2025 – Active Biotech (NASDAQ Stockholm; ACTI) announced today that study results of its clinical drug candidate tasquinimod in heavily pretreated patients with relapsed refractory multiple myeloma (RRMM) are now available on Active Biotech’s website. The results were presented in a poster at the American Society of…
The Annual General Meeting of Active Biotech was held on May 28, 2025. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2024, and that the Company’s accumulated loss shall be carried…
Lund, May 23, 2025 – Active Biotech (NASDAQ Stockholm; ACTI) announced today study results of tasquinimod in combination with ixazomib (proteasome inhibitor, PI), lenalidomide (Imid) and dexamethasone (IRd) in heavily pre-treated patients with relapsed refractory multiple myeloma. The results confirm that tasquinimod has anti-myeloma activity and is well tolerated in…
Lund, May 21, 2025 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has granted the patent application 21749566.2 related to tasquinimod in myelofibrosis, a rare form of blood cancer. “We are very pleased that this significant patent has been granted by the EPO. It…
FIRST QUARTER IN BRIEF US Patent Office granted Active Biotech’s patent application for laquinimod in eye disorders (January 28) Active Biotech announced that the first patient was enrolled in the European clinical study of tasquinimod in myelofibrosis (February 24) Active Biotech announced that the first patient was dosed in the…
Daily treatment with laquinimod eye drops resulted in dose related and therapeutically relevant concentrations of laquinimod in both the anterior and posterior parts of the eye. Laquinimod eye drop treatment was safe and tolerable during 14 days’ administration Lund, May 5, 2025 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced…
The shareholders of Active Biotech AB (publ), Reg. No. 556223-9227, with its registered office in Lund, Sweden, are invited to the Annual General Meeting of shareholders to be held on Wednesday, May 28, 2025 at 5 p.m. CEST in the premises of the Company at Scheelevägen 22, SE-223 63 Lund,…
Active Biotech (NASDAQ Stockholm:ACTI) announces today that the Annual Report 2024 now is available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. “In the past year, we made significant progress in our clinical projects. For 2025, we will focus on advancing the ongoing clinical studies in…
Lund, Sweden, March 10, 2025 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced the first patient has been dosed in the phase II clinical study of tasquinimod in myelofibrosis in the US. The clinical study, entitled Open Label Phase 2 Study of Tasquinimod in Patients with Primary Myelofibrosis, Post-Polycythemia Vera…
Lund Sweden, February 24, 2025 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been included in the phase Ib/II clinical study of tasquinimod in patients with myelofibrosis refractory or ineligible to JAK2 inhibitor treatment. “We are pleased to have enrolled the first patient into the…
EVENTS DURING THE FOURTH QUARTER European Patent Office granted Active Biotech’s patent application for eye drop formulation of laquinimod (October 23) Active Biotech’s clinical trial of tasquinimod in myelofibrosis was approved in Europe (October 30) Preclinical data of tasquinimod in myelofibrosis was presented at ASH 2024 (November 5) Active Biotech…
The number of shares and votes in Active Biotech AB (publ) has changed as a result of the recently completed rights issue. The 164,638,960 shares in relation to which allotment was conditional on that relevant FDI (Foreign Direct Investment) approvals from the Inspectorate of Strategic Products, have been registered in…
Lund, January 28, 2025, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has granted Active Biotech’s US patent application 17/939,109 for laquinimod in eye disorders. “We continue our dedicated work with the laquinimod patent portfolio to optimize protection for its use in sight-threatening eye disorders…
The number of shares and votes in Active Biotech AB (publ) has changed as a result of the recently completed rights issue. Today, the last trading day of the month, there are in total 1,065,525,722 shares and votes in Active Biotech. An additional 164,638,960 shares issued in the rights issue…
In accordance with a decision made by the Annual General Meeting held on May 22, 2024, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2024, and the Chairman of the Board. If a shareholder does not exercise its right…
Lund, December 9, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on tasquinimod, a small molecule immunomodulator in development for myelofibrosis are now available on the company’s website. The data were presented at the 66th American Society of Hematology Annual Meeting (ASH 2024) in San Diego,…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
Lund, November 13, 2024, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has issued a Notice of Allowance for Active Biotech’s patent application related to methods of treating eye diseases associated with excessive vascularization using laquinimod. The patent, which was filed under application no. 17/939,109,…
Lund, November 5, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that an abstract with preclinical data for tasquinimod in myelofibrosis has been accepted for presentation at the 66th American Society of Hematology Annual Meeting in San Diego, December 7-10, 2024 (ASH 2024). The abstract demonstrating efficacy of tasquinimod…
Lund, Sweden, October 30, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the clinical phase I/II study of Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition (HOVON 172 MF) has received full approval from the European Medicines Agency (EMA) and the Institutional Ethics Committees.…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
The Extraordinary General Meeting of Active Biotech was held on October 23, 2024. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was resolved to amend the Articles of Association, whereby the limits for the company’s share capital are changed to not less than…
Lund, October 23 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has granted Active Biotech’s patent application covering a proprietary developed eye drop formulation of laquinimod. The patent “Laquinimod formulation for ocular use”, published on October 23, 2024 under European patent number 4312986,…
THIRD QUARTER IN BRIEF Active Biotech entered agreement with MD Anderson for a clinical study of tasquinimod in myelofibrosis (July 1) Active Biotech provided an update on the clinical phase Ib/IIa study with tasquinimod in relapsed refractory multiple myeloma (July 15) Active Biotech reported intriguing intraocular concentrations achieved in a…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
The shareholders of Active Biotech AB (publ), Reg. No. 556223-9227, with its registered office in Lund, Sweden, are invited to the Extraordinary General Meeting of shareholders to be held on Wednesday, October 23, 2024 at 11 a.m. CEST in the premises of the Company at Scheelevägen 22, SE-223 63 Lund,…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE…
Lund, September 10 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced an update to the ongoing clinical phase I biodistribution study of laquinimod eye drops in patients undergoing vitrectomy. A proprietary formulation of laquinimod for corneal application was developed, taking the specific physico-chemical characteristics of this agent into account,…
SECOND QUARTER IN BRIEF Start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops (April 3) Active Biotech acquired exclusive rights to patents of tasquinimod in combination therapy in multiple myeloma (May 22) Clinical activity and safety of naptumomab and docetaxel in non-small cell lung cancer…
Lund, July 15 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced an update to a clinical study of tasquinimod in patients with relapsed refractory multiple myeloma (RRMM) being conducted at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia. The study is ongoing in its expansion cohort…
Lund, July 1, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into a clinical study agreement for a Phase II investigator-initiated clinical study investigating the use of tasquinimod in myelofibrosis. The study will be led by Lucia Masarova, M.D., assistant professor of Leukemia at The University…
The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program for the company’s employees (Plan 2020/2024). Today, the last trading day of the month, there are in total 361,813,142 shares and votes in Active Biotech. For…
Lund, May 28, 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) announces today that NeoTX Therapeutics, exclusive licensee of naptumomab estafenatox (naptumomab, NAP) from Active Biotech, will present initial results from phase IIa trial with NAP and docetaxel in advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) patients, at the American Society of…
